alexa Immunotherapy Of Hematologic Malignancies And Metastatic Solid Tumors In Experimental Animals And Man | 19850
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Hematology & Blood Disorders

Shimon Slavin
Keynote: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.005
Abstract
Engraftment of T cells or donor lymphocyte infusion (DLI) following allogeneic stem cell transplantation (SCT) results in graft-vs.-tumor effects (GVT) but is accompanied by acute and chronic graft-vs.-host disease (GVHD). GVT effects post SCT can be accomplished by IL-2 activated natural killer (NK) cells prepared by negative selection of CD3+ T cells or by positive selection of CD56+ NK cells. Interestingly, mismatched NK cells are much more effective GVT inducers, yet they cause no GVHD. Based on animal experiments using murine models of B cell leukemia (BCL1) and metastatic breast cancer (4T1) we have documented that GVT effects mediated by intentionally mismatched IL-2 activated killer cells (IMAK), including T, NK & NKT cells, can result in cure when applied at the stage of minimal residual disease (MRD) following conventional or high dose chemotherapy and SCT. Using IMAK with no prior SCT results in consistent rejection of alloreactive donor lymphocytes within one week and as such GVHD is prevented while malignant cells are being attacked as long as donor lymphocytes circulate. More selective GVT effects induced by IMAK against residual malignant cells can be accomplished by targeting killer T, NK & NKT cells against tumor cells by monoclonal or bispecific antibodies against over-expressed antigens (e.g. Erbitux, Avastin or Catumaxomab for solid tumors or MabThera for B cell malignancies). In conclusion, based on observations in mice and man, IMAK provides a safe treatment for patients with residual malignant cells resistant to available anti-cancer agents while avoiding the risk of GVHD.
Biography
Shimon Slavin, MD, Professor of Medicine is currently serving as the Medical & Scientific Director of the International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Tel Aviv, Israel. He pioneered the use of immunotherapy mediated by donor lymphocytes and innovative methods for stem cell transplantation for malignant and non-malignant disorders including treatment of autoimmune diseases and more recently, using multi-potent stem cells for regenerative medicine. He authored 4 books, 660 scientific publications and serves on many editorial boards and many national and international advisory boards. He received many international awards in recognition of his contributions for treatment of malignant and non-malignant disorders.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7